
    
      This is a Phase IIb trial to determine if the delivery of the autologous UCB-MNC product into
      the myocardium of the right ventricle of the heart at the time of Stage II surgical repair
      will provide an improvement in cardiac function, reaching growth and developmental
      milestones, and quality of life, while also providing a reduction in the cumulative days of
      hospitalization following Stage II surgical repair. Long-term improvement in cardiac
      function, reaching growth and developmental milestones, reaching Stage III surgical repair
      pre-op work-up, prolonging time to cardiac transplantation or death, and improving quality of
      life will also be determined.
    
  